Related references
Note: Only part of the references are listed.Optimal strategies for social distancing and testing to control COVID-19
Wongyeong Choi et al.
JOURNAL OF THEORETICAL BIOLOGY (2021)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Relationship of vancomycin trough levels with acute kidney injury risk: an exposure-toxicity meta-analysis
Ioannis Bellos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments
Fabrizio Angaroni et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)
Designing combination therapies using multiple optimal controls
Jesse A. Sharp et al.
JOURNAL OF THEORETICAL BIOLOGY (2020)
Molecular Mechanisms of Colistin-Induced Nephrotoxicity
Zhibo Gai et al.
MOLECULES (2019)
International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Optimal control of vaccination in a vector-borne reaction-diffusion model applied to Zika virus
Tiago Yuzo Miyaoka et al.
JOURNAL OF MATHEMATICAL BIOLOGY (2019)
Optimal control of acute myeloid leukaemia
Jesse A. Sharp et al.
JOURNAL OF THEORETICAL BIOLOGY (2019)
Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical
Luisa Sorli et al.
JOURNAL OF INFECTION (2019)
Optimal Combined Radio- and Anti-Angiogenic Cancer Therapy
Urszula Ledzewicz et al.
JOURNAL OF OPTIMIZATION THEORY AND APPLICATIONS (2019)
Analysis of the clinical antibacterial and antituberculosis pipeline
Ursula Theuretzbacher et al.
LANCET INFECTIOUS DISEASES (2019)
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
Philippe B. Pierrillas et al.
AAPS JOURNAL (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives
Femke de Velde et al.
PHARMACOLOGICAL RESEARCH (2018)
Dosing Guidance for Intravenous Colistin in Critically Ill Patients
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Colistin
Nicolas Gregoire et al.
CLINICAL PHARMACOKINETICS (2017)
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2016)
Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis
M. Jacobs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Optimization of dosing regimens and dosing in special populations
F. B. Sime et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection
Soon-Ee Cheah et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
Matthieu Boisson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale
N. Gregoire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin
Aline Vidal Lacerda Gontijo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study
Luisa Sorli et al.
BMC INFECTIOUS DISEASES (2013)
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Elisabet I. Nielsen et al.
PHARMACOLOGICAL REVIEWS (2013)
Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill
Ami F. Mohamed et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Therapeutic drug monitoring of antimicrobials
Jason A. Roberts et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
J. W. Mouton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization
Elisabet I. Nielsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
S. M. Garonzik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers
W. Couet et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients
Argyris S. Michalopoulos et al.
ANNALS OF INTENSIVE CARE (2011)
Modeling Optimal Intervention Strategies for Cholera
Rachael L. Miller Neilan et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2010)
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance:: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model
Phillip J. Bergen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis
A Michalopoulos et al.
CRITICAL CARE (2005)
Evaluation of colistin as an agent against multi-resistant in Gram-negative bacteria
J Li et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
A rational approach for selection of optimal covariate-based dosing strategies
S Jonsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Optimal control of an HIV immunology model
HR Joshi
OPTIMAL CONTROL APPLICATIONS & METHODS (2002)
Share Paper
